MediGuard - Contrôleur d’interactions médicamenteuses, effets secondaires des médicaments, innocuité des médicaments Neuroscience and Pain Science for Manual Physical Therapists Study: Tree bark compound helps reduce severe pain symptoms naturally (Build 20110413222027) (NaturalNews) A new study published in the journal Nature Chemistry provides new insight into the power of a rare type of tree bark to relieve serious pain. Scientists from the Scripps Research Institute (SRI) in Florida discovered that the bark of the Tabernaemontana divaricata plant, also known as crepe jasmine, contains a compound known as conolidine that appears to be just as effective at treating pain as morphine, but without all the harmful side effects. Glenn Micalizio, an associate professor at the SRI Department of Chemistry, and his colleagues first had to figure out a way to synthesize conolidine in order to study it. Not an opioid itself, conolidine remains a bit of a mystery. Either way, conolidine exhibited no harmful side effects, so its viability as an effective replacement to side effect-producing drugs like morphine is considerable, even without mechanistic details. "Conolidine is a very potent analgesic," said Micalizio. Sources for this story include:
The New England Journal of Medicine ThermoGenesis » Home EM:RAP Cannabis for Spasticity in Multiple Sclerosis Primary Outcome Measures: Change in an objective measurement of spasticity between the pretreatment assessment and the 3- and 7-week assessments [ Time Frame: 7 weeks ] [ Designated as safety issue: Yes ] Secondary Outcome Measures: Differences between active agent and placebo in the changes in Ashworth Scale, Functional System Score, Expanded Disability Status Score, Ambulation Index, Functional Composite Score, and Quality of Life Inventory. [ Time Frame: 7 weeks ] [ Designated as safety issue: Yes ] The treatment of MS is far from satisfactory. For acute attacks, high dose corticosteroids seem to reduce the duration of attacks and to reduce the likelihood of future attacks. Immunomodulatory agents, available in this disease over the last decade, reduce the frequency of severe attacks by about one third. The remainder of the treatments are symptomatic, aimed at reducing the disability already present. Comparisons: Three treatment arms will be compared: